Promoting high-quality clinical research to develop more and better medicines for children

News 14/04/2016

EMA workshop scheduled for 2 June 2016 opens for registration

The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) will hold its 8th annual workshop on 2 June 2016 at the premises of the European Medicines Agency (EMA) in London, UK. The aim of the workshop is to promote high-quality clinical studies in children.

Enpr-EMA brings together research networks, investigators and centres in Europe with recognised expertise in performing paediatric clinical studies. Its mission is to facilitate the conduct of paediatric studies in order to increase the availability of medicines authorised for use in children.

The first day of the workshop will be open to all stakeholders including patients/parents organisations, regulators, Enpr-EMA network representatives, academia, clinical investigators and representatives from the pharmaceutical industry for paediatric studies.

Participants will hear about Enpr-EMA's activities to foster high-quality research in paediatric medicine and will be invited to provide their views on the achievements made so far and the way forward.

Among the highlights of this year's workshop is a panel debate on how ethical aspects in relation to clinical studies in children will be handled in the context of the implementation of the new European Union Clinical Trial Regulation.

Registration for the first day of the workshop is open until 24 May. Please send the completed registration to

The second day of the workshop is reserved for discussions among the members of Enpr-EMA and the Enpr-EMA coordinating group. The coordinating group will define priorities for 2016-2017 based on the feedback received from stakeholders.

Enpr-EMA was launched in 2011 and includes 38 Member organisations. It provides and disseminates good practice guidance, resources and services to medicine developers to help them conduct high-quality paediatric clinical research.

Coordinated by EMA, its actions focus on:

  • fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in children;
  • helping with the recruitment of patients for clinical trials;
  • enabling collaboration between networks and stakeholders;
  • avoiding unnecessary duplication of studies;
  • building up scientific and administrative competence at a European level;
  • promoting European Commission framework programme applications.

Four new networks joined Enpr-EMA in 2015. Information about Enpr-EMA members is available in a fully searchable database.

How useful was this page?

Add your rating